Welcome to our dedicated page for Kewaunee Scienti news (Ticker: KEQU), a resource for investors and traders seeking the latest updates and insights on Kewaunee Scienti stock.
Kewaunee Scientific Corporation (NASDAQ: KEQU) is a manufacturing company specializing in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow developments that affect KEQU stock and Kewaunee’s operations.
Recent news has focused on quarterly and annual financial results, where Kewaunee reports performance for its domestic, international, and corporate segments and discusses trends in sales, profitability, and order backlog. The company also provides updates on non-GAAP metrics such as EBITDA, Segment EBITDA, Adjusted EBITDA, and adjusted net earnings, including the impact of acquisition and integration costs related to NuAire.
Investors and observers can also find coverage of capital structure and financing actions, including debt refinancing, early repayment of seller notes associated with the NuAire acquisition, and amendments to loan agreements. In addition, Kewaunee issues news about share repurchase program amendments and its approach to capital allocation.
Corporate governance and strategic matters appear in items such as board appointments, proxy-related communications, and disclosures about strategic investments in people, processes, and technology at the corporate level. Operational and commercial updates include participation in industry events like the Arablab Live trade show and information about Kewaunee’s global footprint, including its manufacturing facilities in Statesville, North Carolina and Bangalore, India and its sales offices in multiple countries.
By reviewing the KEQU news feed on this page, readers can track how Kewaunee communicates about its financial performance, acquisitions, international activities, and corporate initiatives over time.
Unusual Machines (NYSE American: UMAC) received a $2.1 million purchase order for NDAA-compliant drone components to support domestically assembled drone systems for defense and government applications.
The order will be fulfilled across Q1 and Q2 2026, using existing manufacturing capacity and inventory. Components include Rotor Riot Brave flight controllers and ESCs, Fat Shark Aura analog cameras and VTX, HDO+ headsets, and motors. Management said operational alignment enables rapid execution to meet compressed government timelines.
Kewaunee Scientific (NASDAQ: KEQU) reported fiscal 2026 second quarter results for the period ended October 31, 2025. Net sales were $70.096 million, up 46.8% year-over-year. EBITDA was $5.79 million, higher than the prior-year quarter. Pre-tax earnings were $3.453 million (down 12.2%) and net earnings were $2.445 million. Diluted EPS was $0.82.
The company reported an
Kewaunee Scientific (NASDAQ: KEQU) announced on Dec 4, 2025 that it fully repaid its Seller Notes tied to the Nu Aire acquisition. The Seller Notes had an original principal of $23.0 million and were scheduled to mature Nov 1, 2027. Repayment was funded via an amendment to the Nov 1, 2024 loan agreement with PNC, which provided a $10.0 million term loan and permitted use of available revolving credit.
The company said the transactions lower overall debt, reduce the effective interest rate, and materially cut expected future interest expense while supporting strategic growth plans.
Kewaunee Scientific (NASDAQ: KEQU) announced it will release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. The company said the release will be posted on its website and accompanying materials will be available at www.kewaunee.com.
The release reiterates company background: Kewaunee designs and manufactures laboratory and healthcare furniture, operates manufacturing sites in Statesville and Bangalore, and recently acquired subsidiary Nu Aire, a maker of biological safety cabinets and lab equipment. The notice includes customary forward-looking statements and risk factors and provides an investor contact.
Kewaunee Scientific Corporation (NASDAQ: KEQU), a leading manufacturer of laboratory, healthcare, and technical furniture products, has appointed J. Jette Campbell, CPA to its Board of Directors, effective September 10, 2025. Campbell brings extensive experience from leadership roles at PepsiCo, Frito-Lay, and Griffin LLC, as well as expertise as a partner at Carl Marks Advisors.
The appointment comes at a strategic time as Kewaunee focuses on accelerating growth through organic and inorganic means. The company, founded in 1906, operates manufacturing facilities in Statesville, North Carolina and Bangalore, India, with its recently acquired subsidiary Nu Aire based in Minnesota, complementing Kewaunee's product portfolio with biological safety cabinets and laboratory equipment.
Kewaunee Scientific (NASDAQ: KEQU) reported strong Q1 FY2026 results with sales reaching $71.1 million, up 46.9% year-over-year. The company achieved net earnings of $3.1 million ($1.04 per diluted share), compared to $2.2 million ($0.74 per share) in the prior year.
The company's order backlog stood at $205.0 million as of July 31, 2025, up from $159.4 million year-over-year. Domestic segment sales increased 53.0% to $54.4 million, while International segment sales grew 30.2% to $16.8 million. The growth was partially driven by the incorporation of Nu Aire's results, following its acquisition in November 2024.
Despite anticipating uneven quarterly performance for the remainder of FY2026, management expects to deliver improved unadjusted EBITDA compared to FY2025, while continuing strategic investments in corporate infrastructure.
[ "Sales increased significantly by 46.9% to $71.1 million year-over-year", "Net earnings grew 41% to $3.1 million compared to prior year", "Strong order backlog of $205.0 million, up 28.6% from prior year", "Domestic segment sales surged 53.0% to $54.4 million", "International segment sales increased 30.2% to $16.8 million", "Debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1" ]Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced its participation in the 2025 Arablab Live tradeshow in Dubai from September 23-25. The company will showcase its comprehensive portfolio, including products from its newly acquired subsidiary NuAire, and its healthcare brand EVERHUTCH.
Visitors can explore Kewaunee's booth at Hall 1, Stand F80 of the Dubai World Trade Centre, featuring demonstrations of new Revit design tools for laboratory planning. The presentation will highlight the company's integrated expertise in laboratory infrastructure, biosafety, healthcare environments, and data-informed lab design through its partnership with Koncepo.
Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced plans to release its first quarter fiscal year 2026 financial results on September 10, 2025 after market close. The company, founded in 1906, is a global leader in laboratory, healthcare, and technical furniture products manufacturing.
Kewaunee's portfolio includes steel and wood casework, fume hoods, modular systems, and biological safety cabinets. The company operates manufacturing facilities in Statesville, North Carolina and Bangalore, India, with sales offices across the US, India, Saudi Arabia, and Singapore. Through its recently acquired subsidiary Nu Aire, the company also manufactures laboratory products in Minnesota and maintains partnerships in the Netherlands and China.
Kewaunee Scientific Corporation (NASDAQ: KEQU) reported strong financial results for Q4 and fiscal year 2025. Q4 sales reached $77.1 million, up 36.1% year-over-year, with net earnings of $4.85 million and diluted EPS of $1.63. The company's order backlog stood at $214.6 million as of April 30, 2025.
The company completed the acquisition of Nu Aire, Inc. on November 1, 2024, strengthening its laboratory equipment portfolio. For the full fiscal year 2025, sales increased 18% to $240.5 million, with net earnings of $11.4 million. Adjusted for acquisition costs, fiscal year 2025 adjusted diluted EPS was $5.37, compared to $4.19 in the prior year.
The Domestic segment showed particularly strong performance with sales up 54.7% in Q4, while International segment sales increased by 3.9%. The company maintains a healthy financial position with $17.2 million in cash and a debt-to-equity ratio of 0.99-to-1.
FAQ
What is the current stock price of Kewaunee Scienti (KEQU)?
What is the market cap of Kewaunee Scienti (KEQU)?
